The Nordics are undisputedly a global powerhouse for innovation and early-stage science. Yet, the region often struggles to scale these innovations into independent, global industrial players. Too often, our most promising assets are acquired by international pharma giants before they reach their full commercial potential.

In this high-level panel, we bring together the region’s heavyweight investors, managing the largest pools of capital, to discuss the strategic roadmap for 2026 and beyond. Do we have the financial depth and risk appetite to back companies ”all the way,” or is the early-exit model a necessity? We debate the power of syndication, the need for larger ticket sizes, and what it will actually take for Nordic Venture Capital to build the next Novo Nordisk.

Panelists includes:

Andreas Lindblom, Managing Partner, Sciety
Ulrica Slåne Bjerne, CIO, Arctic Aurora LifeScience
Max Odlander, Partner, HealthCap
Everett Kamin, CIO, Gemini Capital Partners & CIO, Silverstein Dream Foundation

All moderated by: Nina Rawal, Investment Committee Member, We Venture Capital

What does the future of healthcare look like through the lens of those who fund it? Join a panel of premier Nordic investors as they explore the next wave of MedTech breakthroughs. The discussion will delve into where the region’s biggest investment opportunities lie, how geopolitical shifts impact funding timelines, and how we turn brilliant Scandinavian science into sustainable, global businesses.

Panelists includes:

Svana Gunnarsdóttir, Co-founder & Managing Partner, Frumtak Ventures
Karin Leire, Investment Manager, Segula Medical Acceleration
Kristofer Klerfalk, Managing Partner, Life Science Invest
Fredrik Andersson, CEO, Bonnier Healthcare

All moderated by: Stina Wallmark, Investment Director, VOIMA Ventures

In this panel, active European life science investors break down what they look for in cross-border deals, how their investment criteria differ, and what Nordic founders must know to pitch successfully outside the region. Expect a frank, practical discussion and actionable strategies for Nordic biotech, medtech, and healthtech ventures seeking international growth.

Panelists includes:
Melissa Simon, Partner, Wieland Capital
Laurens De Vries, Investor, Opdorp Finance: Vereeckens Family Office
Maria Nyåkern, Founder & Investor, Nyakern Nexus Investments 
All moderated by: Felix Borrebaeck, Business Developer andVenture Writer, BioStock

Family offices answer to no one – no LPs, no exit deadline. They play their own money, on their own timeline. In life science, where a drug can take 15 years to reach approval and one failed trial can wipe out everything overnight, that patience is an advantage few others can afford. No fund to raise, no clock to beat – do FO:s even need a strategy? Join us to find out.

Panelists include:

Laurent Pacheco, Managing Partner, IFOAH & Partner, Solas BioVentures
Hugo Mörse, Partner, Bonit Capital & Managing Director, Leksell Social Ventures
Jan Erik Smith, Partner, GOBIA Enterprises
Moderated by: Everett Kamin, CIO at Gemini Capital Partners & CIO at Silverstein Dream Foundation